{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:24:24Z","timestamp":1790767464982,"version":"4.1.0"},"reference-count":174,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":1782,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s13311-018-0655-y","type":"journal-article","created":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T14:23:08Z","timestamp":1534429388000},"page":"928-942","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":204,"title":["Pompe Disease: From Basic Science to Therapy"],"prefix":"10.1016","volume":"15","author":[{"given":"Lara","family":"Kohler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Puertollano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9519-3535","authenticated-orcid":false,"given":"Nina","family":"Raben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-018-0655-y_bib1","first-page":"304","article-title":"Over idiopatische hypertrophie van het hart","volume":"76","author":"Pompe","year":"1932","journal-title":"Ned Tijdschr Geneeskd"},{"key":"10.1007\/s13311-018-0655-y_bib2","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/BF02248461","article-title":"Zum klinischen Bild der Glykogen-Speicherungs-Krankheit (Glykogenose)","volume":"52","author":"Bischoff","year":"1932","journal-title":"Zeitschrift fur Kinderheikunde"},{"key":"10.1007\/s13311-018-0655-y_bib3","first-page":"222","article-title":"Uber angeborene Glykogenspeicher-Krankheit des Herzens. \u201cThesaurismosis glycogenica\u201d (v. Gierke)","volume":"90","author":"Putschar and Walter","year":"1932","journal-title":"Beitr Pathol Anat Allg Pathol"},{"issue":"1\u20132","key":"10.1007\/s13311-018-0655-y_bib4","first-page":"38","article-title":"Enzymes and glycogen structure in glycogenosis","volume":"10","author":"Cori","year":"1954","journal-title":"Osterreichische Zeitschrift fur Kinderheilkunde und Kinderfursorge"},{"issue":"4","key":"10.1007\/s13311-018-0655-y_bib5","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1042\/bj0600604","article-title":"Tissue fractionation studies. 6. Intracellular distribution patterns of enzymes in rat-liver tissue","volume":"60","author":"De Duve","year":"1955","journal-title":"Biochem J"},{"key":"10.1007\/s13311-018-0655-y_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1042\/bj0860011","article-title":"Alpha-glucosidase deficiency in generalize glycogen storage disease (Pompe's disease)","volume":"86","author":"Hers","year":"1963","journal-title":"Biochem J"},{"issue":"3","key":"10.1007\/s13311-018-0655-y_bib7","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1016\/S0021-9258(18)53985-5","article-title":"Structural and functional changes of lysosomal acid alpha-glucosidase during intracellular transport and maturation","volume":"268","author":"Wisselaar","year":"1993","journal-title":"J Biol Chem"},{"issue":"6","key":"10.1007\/s13311-018-0655-y_bib8","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1002\/j.1460-2075.1988.tb02998.x","article-title":"Primary structure and processing of lysosomal alpha-glucosidase; homology with the intestinal sucrase-isomaltase complex","volume":"7","author":"Hoefsloot","year":"1988","journal-title":"EMBO J"},{"issue":"Pt 3","key":"10.1007\/s13311-018-0655-y_bib9","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1042\/bj2890681","article-title":"Human lysosomal alpha-glucosidase: functional characterization of the glycosylation sites","volume":"289","author":"Hermans","year":"1993","journal-title":"Biochem J"},{"issue":"8","key":"10.1007\/s13311-018-0655-y_bib10","doi-asserted-by":"crossref","first-page":"6780","DOI":"10.1074\/jbc.M404008200","article-title":"Lysosomal acid alpha-glucosidase consists of four different peptides processed from a single chain precursor","volume":"280","author":"Moreland","year":"2005","journal-title":"J Bio lChem"},{"issue":"1","key":"10.1007\/s13311-018-0655-y_bib11","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ajmg.c.31318","article-title":"The genotype-phenotype correlation in Pompe disease","volume":"160","author":"Kroos","year":"2012","journal-title":"Am J Med Genet C: Semin Med Genet"},{"issue":"4","key":"10.1007\/s13311-018-0655-y_bib12","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/GIM.0b013e3181d2900e","article-title":"The angiotensin-converting enzyme insertion\/deletion polymorphism modifies the clinical outcome in patients with Pompe disease","volume":"12","author":"de Filippi","year":"2010","journal-title":"Genet Med"},{"issue":"2","key":"10.1007\/s13311-018-0655-y_bib13","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1042\/bj2720493","article-title":"Characterization of the human lysosomal alpha-glucosidase gene","volume":"272","author":"Hoefsloot","year":"1990","journal-title":"Biochem J"},{"issue":"2","key":"10.1007\/s13311-018-0655-y_bib14","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1089\/dna.1990.9.85","article-title":"Sequence of the cDNA and 5\u2032-flanking region for human acid alpha-glucosidase, detection of an intron in the 5\u2032 untranslated leader sequence, definition of 18-bp polymorphisms, and differences with previous cDNA and amino acid sequences","volume":"9","author":"Martiniuk","year":"1990","journal-title":"DNA Cell Biol"},{"issue":"3","key":"10.1007\/s13311-018-0655-y_bib15","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/BF02185782","article-title":"Localization and ordering of acid alpha-glucosidase (GAA) and thymidine kinase (TK1) by fluorescence in situ hybridization","volume":"97","author":"Kuo","year":"1996","journal-title":"Hum Genet"},{"issue":"12","key":"10.1007\/s13311-018-0655-y_bib16","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1093\/hmg\/3.12.2231","article-title":"Aberrant splicing in adult onset glycogen storage disease type II (GSDII): molecular identification of an IVS1 (-13T\u2013>G) mutation in a majority of patients and a novel IVS10 (+1GT\u2013>CT) mutation","volume":"3","author":"Huie","year":"1994","journal-title":"Hum Mol Genet"},{"issue":"4","key":"10.1007\/s13311-018-0655-y_bib17","first-page":"887","article-title":"Leaky splicing mutation in the acid maltase gene is associated with delayed onset of glycogenosis type II","volume":"56","author":"Boerkoel","year":"1995","journal-title":"Am J Hum Genet"},{"issue":"7","key":"10.1007\/s13311-018-0655-y_bib18","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/hmg\/5.7.995","article-title":"A model of mRNA splicing in adult lysosomal storage disease (glycogenosis type II)","volume":"5","author":"Raben","year":"1996","journal-title":"Hum Mol Genet"},{"issue":"9","key":"10.1007\/s13311-018-0655-y_bib19","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.nmd.2015.07.002","article-title":"Homozygosity for the common GAA gene splice site mutation c.-32-13T>G in Pompe disease is associated with the classical adult phenotypical spectrum","volume":"25","author":"Musumeci","year":"2015","journal-title":"Neuromuscul Disord"},{"issue":"12","key":"10.1007\/s13311-018-0655-y_bib20","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1093\/hmg\/3.12.2213","article-title":"The effect of a single base pair deletion (delta T525) and a C1634T missense mutation (pro545leu) on the expression of lysosomal alpha-glucosidase in patients with glycogen storage disease type II","volume":"3","author":"Hermans","year":"1994","journal-title":"Hum Mol Genet"},{"issue":"1","key":"10.1007\/s13311-018-0655-y_bib21","first-page":"85","article-title":"Frequency of mutations for glycogen storage disease type II in different populations: the delta525T and deltaexon 18 mutations are not generally \u201ccommon\u201d in white populations","volume":"36","author":"Hirschhorn","year":"1999","journal-title":"J Med Genet"},{"issue":"6","key":"10.1007\/s13311-018-0655-y_bib22","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1159\/000022938","article-title":"Evidence for a founder effect in Sicilian patients with glycogen storage disease type II","volume":"50","author":"Dagnino","year":"2000","journal-title":"Hum Hered"},{"key":"10.1007\/s13311-018-0655-y_bib23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1750-1172-7-35","article-title":"A cross-sectional single-centre study on the spectrum of Pompe disease, German patients: molecular analysis of the GAA gene, manifestation and genotype-phenotype correlations","volume":"7","author":"Herzog","year":"2012","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"10.1007\/s13311-018-0655-y_bib24","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/(SICI)1098-1004(1998)11:4<306::AID-HUMU8>3.0.CO;2-S","article-title":"Frequent mutation in Chinese patients with infantile type of GSD II in Taiwan: evidence for a founder effect","volume":"11","author":"Shieh","year":"1998","journal-title":"Hum Mutat"},{"issue":"4","key":"10.1007\/s13311-018-0655-y_bib25","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1086\/301788","article-title":"The African origin of the common mutation in African American patients with glycogen-storage disease type II","volume":"62","author":"Becker","year":"1998","journal-title":"Am J Hum Genet"},{"issue":"3","key":"10.1007\/s13311-018-0655-y_bib26","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ymgme.2009.03.004","article-title":"High frequency of acid alpha-glucosidase pseudodeficiency complicates newborn screening for glycogen storage disease type II in the Japanese population","volume":"97","author":"Kumamoto","year":"2009","journal-title":"Mol Genet Metab"},{"issue":"4","key":"10.1007\/s13311-018-0655-y_bib27","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ymgme.2009.12.014","article-title":"Genetic heterozygosity and pseudodeficiency in the Pompe disease newborn screening pilot program","volume":"99","author":"Labrousse","year":"2010","journal-title":"Mol Genet Metab"},{"issue":"4","key":"10.1007\/s13311-018-0655-y_bib28","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jpeds.2014.10.068","article-title":"Long-term prognosis of patients with infantile-onset Pompe disease diagnosed by newborn screening and treated since birth","volume":"166","author":"Chien","year":"2015","journal-title":"J Pediatr"},{"issue":"2","key":"10.1007\/s13311-018-0655-y_bib29","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1542\/peds.112.2.332","article-title":"The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature","volume":"112","author":"van den Hout","year":"2003","journal-title":"Pediatrics"},{"issue":"5","key":"10.1007\/s13311-018-0655-y_bib30","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J Pediatr"},{"issue":"2","key":"10.1007\/s13311-018-0655-y_bib31","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1067\/mpd.2000.107112","article-title":"Identification of two subtypes of infantile acid maltase deficiency","volume":"137","author":"Slonim","year":"2000","journal-title":"J Pediatr"},{"issue":"3","key":"10.1007\/s13311-018-0655-y_bib32","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2016.12.004","article-title":"The emerging phenotype of late-onset Pompe disease: A systematic literature review","volume":"120","author":"Chan","year":"2017","journal-title":"Mol Genet Metab"},{"issue":"8","key":"10.1007\/s13311-018-0655-y_bib33","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00415-005-0922-9","article-title":"The natural course of non-classic Pompe's disease; a review of 225 published cases","volume":"252","author":"Winkel","year":"2005","journal-title":"J Neurol"},{"issue":"5","key":"10.1007\/s13311-018-0655-y_bib34","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","article-title":"Pompe disease diagnosis and management guideline","volume":"8","author":"Kishnani","year":"2006","journal-title":"Genet Med"},{"issue":"2","key":"10.1007\/s13311-018-0655-y_bib35","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.nmd.2015.11.009","article-title":"Pulmonary function tests (maximum inspiratory pressure, maximum expiratory pressure, vital capacity, forced vital capacity) predict ventilator use in late-onset Pompe disease","volume":"26","author":"Johnson","year":"2016","journal-title":"Neuromuscul Disord"},{"key":"10.1007\/s13311-018-0655-y_bib36","first-page":"1","article-title":"Diagnosis of Pompe disease: muscle biopsy vs blood-based assays","author":"Vissing","year":"2013","journal-title":"JAMA Neurol"},{"issue":"5","key":"10.1007\/s13311-018-0655-y_bib37","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.nmd.2011.11.003","article-title":"Acid phosphatase-positive globular inclusions is a good diagnostic marker for two patients with adult-onset Pompe disease lacking disease specific pathology","volume":"22","author":"Tsuburaya","year":"2012","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"10.1007\/s13311-018-0655-y_bib38","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/2051-5960-2-2","article-title":"The value of muscle biopsies in Pompe disease: identifying lipofuscin inclusions in juvenile- and adult-onset patients","volume":"2","author":"Feeney","year":"2014","journal-title":"Acta Neuropathologica Communications"},{"issue":"9646","key":"10.1007\/s13311-018-0655-y_bib39","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe's disease","volume":"372","author":"Van der Ploeg","year":"2008","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1007\/s13311-018-0655-y_bib40","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1542\/peds.2016-0280D","article-title":"Pompe Disease Newborn Screening Working G. The Initial Evaluation of Patients After Positive Newborn Screening: Recommended Algorithms Leading to a Confirmed Diagnosis of Pompe Disease","volume":"140","author":"Burton","year":"2017","journal-title":"Pediatrics"},{"issue":"1","key":"10.1007\/s13311-018-0655-y_bib41","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/BF02889849","article-title":"Infantile acid maltase deficiency. I. Muscle fiber destruction after lysosomal rupture4","volume":"45","author":"Griffin","year":"1984","journal-title":"Virchows Arch Cell Pathol Mol Pathol"},{"issue":"12","key":"10.1007\/s13311-018-0655-y_bib42","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/labinvest.3700484","article-title":"Characterization of pre- and post-treatment pathology after enzyme replacement therapy for pompe disease","volume":"86","author":"Thurberg","year":"2006","journal-title":"Lab Investig"},{"issue":"5","key":"10.1007\/s13311-018-0655-y_bib43","doi-asserted-by":"crossref","first-page":"719","DOI":"10.4161\/auto.19469","article-title":"Autophagy in lysosomal storage disorders","volume":"8","author":"Lieberman","year":"2012","journal-title":"Autophagy"},{"issue":"11","key":"10.1007\/s13311-018-0655-y_bib44","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nrm2245","article-title":"Autophagy: from phenomenology to molecular understanding in less than a decade","volume":"8","author":"Klionsky","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"7","key":"10.1007\/s13311-018-0655-y_bib45","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s00018-011-0865-5","article-title":"Microautophagy: lesser-known self-eating","volume":"69","author":"Li","year":"2012","journal-title":"Cell Mol Life Sci"},{"issue":"Pt 4","key":"10.1007\/s13311-018-0655-y_bib46","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1242\/jcs.073874","article-title":"Chaperone-mediated autophagy at a glance","volume":"124","author":"Kaushik","year":"2011","journal-title":"J Cell Sci"},{"issue":"2","key":"10.1007\/s13311-018-0655-y_bib47","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ceb.2009.11.014","article-title":"Mammalian autophagy: core molecular machinery and signaling regulation","volume":"22","author":"Yang","year":"2010","journal-title":"Curr Opin Cell Biol"},{"issue":"1","key":"10.1007\/s13311-018-0655-y_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15548627.2015.1100356","article-title":"Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)","volume":"12","author":"Klionsky","year":"2016","journal-title":"Autophagy"},{"issue":"21","key":"10.1007\/s13311-018-0655-y_bib49","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1093\/emboj\/19.21.5720","article-title":"LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing","volume":"19","author":"Kabeya","year":"2000","journal-title":"EMBO J"},{"issue":"3","key":"10.1007\/s13311-018-0655-y_bib50","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/brain\/93.3.599","article-title":"Acid maltase deficiency in adults: studies in four cases of a syndrome which may mimic muscular dystrophy or other myopathies","volume":"93","author":"Engel","year":"1970","journal-title":"Brain"},{"issue":"6","key":"10.1007\/s13311-018-0655-y_bib51","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ymthe.2006.08.009","article-title":"Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in pompe disease","volume":"14","author":"Fukuda","year":"2006","journal-title":"Mol Ther"},{"issue":"1","key":"10.1007\/s13311-018-0655-y_bib52","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4161\/auto.5.1.7293","article-title":"When more is less: excess and deficiency of autophagy coexist in skeletal muscle in Pompe disease","volume":"5","author":"Raben","year":"2009","journal-title":"Autophagy"},{"issue":"6","key":"10.1007\/s13311-018-0655-y_bib53","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4161\/auto.4591","article-title":"Deconstructing Pompe disease by analyzing single muscle fibers","volume":"3","author":"Raben","year":"2007","journal-title":"Autophagy"},{"issue":"1","key":"10.1007\/s13311-018-0655-y_bib54","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s11910-003-0040-y","article-title":"Autophagic vacuolar myopathies","volume":"3","author":"Nishino","year":"2003","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1007\/s13311-018-0655-y_bib55","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/emmm.201202176","article-title":"Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease","volume":"5","author":"Spampanato","year":"2013","journal-title":"EMBO Mol Med"},{"key":"10.1007\/s13311-018-0655-y_bib56","doi-asserted-by":"crossref","DOI":"10.1111\/nan.12214","article-title":"Impaired autophagy affects acid alpha-glucosidase processing and enzyme replacement therapy efficacy in late-onset glycogen storage disease type II","author":"Nascimbeni","year":"2015","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"1","key":"10.1007\/s13311-018-0655-y_bib57","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrm3028","article-title":"Mechanisms of mitophagy","volume":"12","author":"Youle","year":"2011","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"5","key":"10.1007\/s13311-018-0655-y_bib58","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1365-2990.2007.00839.x","article-title":"Adult-onset glycogen storage disease type 2: clinico-pathological phenotype revisited","volume":"33","author":"Schoser","year":"2007","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"2","key":"10.1007\/s13311-018-0655-y_bib59","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/15548627.2015.1009779","article-title":"Defects in calcium homeostasis and mitochondria can be reversed in Pompe disease","volume":"11","author":"Lim","year":"2015","journal-title":"Autophagy"},{"issue":"4","key":"10.1007\/s13311-018-0655-y_bib60","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00401-010-0732-8","article-title":"High-density areas on muscle CT in childhood-onset Pompe disease are caused by excess calcium accumulation","volume":"120","author":"Ishigaki","year":"2010","journal-title":"Acta Neuropathol"},{"issue":"5","key":"10.1007\/s13311-018-0655-y_bib61","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jbiomech.2004.05.040","article-title":"Effects of non-contractile inclusions on mechanical performance of skeletal muscle","volume":"38","author":"Drost","year":"2005","journal-title":"J Biomech"},{"key":"10.1007\/s13311-018-0655-y_bib62","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3389\/fnagi.2014.00177","article-title":"Pompe disease: from pathophysiology to therapy and back again","volume":"6","author":"Lim","year":"2014","journal-title":"Front Aging Neurosci"},{"key":"10.1007\/s13311-018-0655-y_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.tcb.2014.03.003","article-title":"Regulation of mTORC1 by amino acids","author":"Bar-Peled","year":"2014","journal-title":"Trends Cell Biol"},{"key":"10.1007\/s13311-018-0655-y_bib64","doi-asserted-by":"crossref","first-page":"788","DOI":"10.3389\/fphys.2017.00788","article-title":"mTOR as a key regulator in maintaining skeletal muscle mass","volume":"8","author":"Yoon","year":"2017","journal-title":"Front Physiol"},{"key":"10.1007\/s13311-018-0655-y_bib65","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201606547","article-title":"Modulation of mTOR signaling as a strategy for the treatment of Pompe disease","author":"Lim","year":"2017","journal-title":"EMBO Mol Med"},{"issue":"3853","key":"10.1007\/s13311-018-0655-y_bib66","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1126\/science.162.3853.570","article-title":"Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts","volume":"162","author":"Fratantoni","year":"1968","journal-title":"Science"},{"key":"10.1007\/s13311-018-0655-y_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.biochem.031209.093756","article-title":"From serendipity to therapy","volume":"80","author":"Neufeld","year":"2011","journal-title":"Annu Rev Biochem"},{"issue":"21","key":"10.1007\/s13311-018-0655-y_bib68","doi-asserted-by":"crossref","first-page":"12115","DOI":"10.1016\/S0021-9258(18)63825-6","article-title":"Mannose 6-phosphate receptors and lysosomal enzyme targeting","volume":"264","author":"Dahms","year":"1989","journal-title":"J Biol Chem"},{"issue":"9227","key":"10.1007\/s13311-018-0655-y_bib69","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(00)02533-2","article-title":"Recombinant human alpha-glucosidase from rabbit milk in Pompe patients","volume":"356","author":"Van den Hout","year":"2000","journal-title":"Lancet"},{"issue":"5","key":"10.1007\/s13311-018-0655-y_bib70","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1542\/peds.113.5.e448","article-title":"Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk","volume":"113","author":"Van den Hout","year":"2004","journal-title":"Pediatrics"},{"issue":"2","key":"10.1007\/s13311-018-0655-y_bib71","first-page":"132","article-title":"Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I\/II clinical trial","volume":"3","author":"Amalfitano","year":"2001","journal-title":"Genet Med"},{"issue":"2","key":"10.1007\/s13311-018-0655-y_bib72","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"issue":"3","key":"10.1007\/s13311-018-0655-y_bib73","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1203\/PDR.0b013e3181b24e94","article-title":"Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease","volume":"66","author":"Kishnani","year":"2009","journal-title":"Pediatr Res"},{"issue":"3","key":"10.1007\/s13311-018-0655-y_bib74","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/GIM.0b013e31819d0996","article-title":"Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease","volume":"11","author":"Nicolino","year":"2009","journal-title":"Genet Med"},{"issue":"6","key":"10.1007\/s13311-018-0655-y_bib75","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s10545-010-9206-3","article-title":"Treatment of infantile Pompe disease with alglucosidase alpha: the UK experience","volume":"33","author":"Chakrapani","year":"2010","journal-title":"J Inherit Metab Dis"},{"key":"10.1007\/s13311-018-0655-y_bib76","article-title":"Outcome of patients with classical infantile pompe disease receiving enzyme replacement therapy in Germany","author":"Hahn","year":"2015","journal-title":"JIMD Reports"},{"issue":"3","key":"10.1007\/s13311-018-0655-y_bib77","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s10545-011-9404-7","article-title":"Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy","volume":"35","author":"van Gelder","year":"2012","journal-title":"J Inherit Metab Dis"},{"issue":"9","key":"10.1007\/s13311-018-0655-y_bib78","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/gim.2012.44","article-title":"The emerging phenotype of long-term survivors with infantile Pompe disease","volume":"14","author":"Prater","year":"2012","journal-title":"Genet Med"},{"issue":"3","key":"10.1007\/s13311-018-0655-y_bib79","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s10545-015-9912-y","article-title":"Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study","volume":"39","author":"van Gelder","year":"2016","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"10.1007\/s13311-018-0655-y_bib80","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/dmcn.13740","article-title":"Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain","volume":"60","author":"Ebbink","year":"2018","journal-title":"Dev Med Child Neurol"},{"issue":"8","key":"10.1007\/s13311-018-0655-y_bib81","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/GIM.0b013e3182174703","article-title":"The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease","volume":"13","author":"Banugaria","year":"2011","journal-title":"Genet Med"},{"issue":"2","key":"10.1007\/s13311-018-0655-y_bib82","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s10545-014-9707-6","article-title":"Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease","volume":"38","author":"van Gelder","year":"2015","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"10.1007\/s13311-018-0655-y_bib83","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ymgme.2009.08.003","article-title":"Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants","volume":"99","author":"Kishnani","year":"2010","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1007\/s13311-018-0655-y_bib84","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/gim.2011.4","article-title":"Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease","volume":"14","author":"Messinger","year":"2012","journal-title":"Genet Med"},{"issue":"6","key":"10.1007\/s13311-018-0655-y_bib85","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0067052","article-title":"Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT","volume":"8","author":"Banugaria","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"10.1007\/s13311-018-0655-y_bib86","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/gim.2012.110","article-title":"Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease","volume":"15","author":"Banugaria","year":"2013","journal-title":"Genet Med"},{"issue":"4","key":"10.1007\/s13311-018-0655-y_bib87","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ymgme.2010.08.009","article-title":"High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa","volume":"101","author":"de Vries","year":"2010","journal-title":"Mol Genet Metab"},{"issue":"3","key":"10.1007\/s13311-018-0655-y_bib88","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ymgme.2012.04.027","article-title":"The impact of antibodies in late-onset Pompe disease: a case series and literature review","volume":"106","author":"Patel","year":"2012","journal-title":"Mol Genet Metab"},{"issue":"Suppl 1","key":"10.1007\/s13311-018-0655-y_bib89","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1542\/peds.2016-0280E","article-title":"Management of confirmed newborn-screened patients with Pompe disease across the disease spectrum","volume":"140","author":"Kronn","year":"2017","journal-title":"Pediatrics"},{"issue":"15","key":"10.1007\/s13311-018-0655-y_bib90","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","article-title":"A randomized study of alglucosidase alfa in late-onset Pompe's disease","volume":"362","author":"Van der Ploeg","year":"2010","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1007\/s13311-018-0655-y_bib91","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/mus.21025","article-title":"Clinical features of late-onset Pompe disease: a prospective cohort study","volume":"38","author":"Wokke","year":"2008","journal-title":"Muscle Nerve"},{"issue":"3","key":"10.1007\/s13311-018-0655-y_bib92","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ymgme.2012.09.015","article-title":"Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa","volume":"107","author":"van der Ploeg","year":"2012","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.1007\/s13311-018-0655-y_bib93","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00415-009-5275-3","article-title":"Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial","volume":"257","author":"Strothotte","year":"2010","journal-title":"J Neurol"},{"issue":"12","key":"10.1007\/s13311-018-0655-y_bib94","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.nmd.2010.07.277","article-title":"Effect of enzyme therapy in juvenile patients with Pompe disease: a three-year open-label study","volume":"20","author":"van Capelle","year":"2010","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"10.1007\/s13311-018-0655-y_bib95","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s10545-010-9201-8","article-title":"Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II","volume":"33","author":"Bembi","year":"2010","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"10.1007\/s13311-018-0655-y_bib96","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1007\/s00415-011-6293-5","article-title":"Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years","volume":"259","author":"Angelini","year":"2012","journal-title":"J Neurol"},{"issue":"4","key":"10.1007\/s13311-018-0655-y_bib97","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00415-012-6636-x","article-title":"Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review","volume":"260","author":"Toscano","year":"2013","journal-title":"J Neurol"},{"issue":"4","key":"10.1007\/s13311-018-0655-y_bib98","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00415-016-8219-8","article-title":"Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis","volume":"264","author":"Schoser","year":"2017","journal-title":"J Neurol"},{"issue":"6","key":"10.1007\/s13311-018-0655-y_bib99","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s10545-014-9728-1","article-title":"Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS-LSD cohort study","volume":"37","author":"Anderson","year":"2014","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"10.1007\/s13311-018-0655-y_bib100","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ymgme.2013.03.016","article-title":"Enzyme replacement therapy and fatigue in adults with Pompe disease","volume":"109","author":"Gungor","year":"2013","journal-title":"Mol Genet Metab"},{"key":"10.1007\/s13311-018-0655-y_bib101","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1750-1172-8-49","article-title":"Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study","volume":"8","author":"Gungor","year":"2013","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"10.1007\/s13311-018-0655-y_bib102","first-page":"723","article-title":"Quantitation of Mr 46000 and Mr 300000 mannose 6-phosphate receptors in human cells and tissues","volume":"23","author":"Wenk","year":"1991","journal-title":"Biochem Int"},{"issue":"6","key":"10.1007\/s13311-018-0655-y_bib103","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/mt.2009.37","article-title":"Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease","volume":"17","author":"Zhu","year":"2009","journal-title":"Mol Ther"},{"issue":"3","key":"10.1007\/s13311-018-0655-y_bib104","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nrm1050","article-title":"Mannose 6-phosphate receptors: new twists in the tale","volume":"4","author":"Ghosh","year":"2003","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"9","key":"10.1007\/s13311-018-0655-y_bib105","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1073\/pnas.0308728100","article-title":"Glycosylation-independent targeting enhances enzyme delivery to lysosomes and decreases storage in mucopolysaccharidosis type VII mice","volume":"101","author":"LeBowitz","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-018-0655-y_bib106","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1074\/jbc.M112.438663","article-title":"Glycosylation-independent lysosomal targeting of acid alpha-glucosidase enhances muscle glycogen clearance in Pompe mice","volume":"288","author":"Maga","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1007\/s13311-018-0655-y_bib107","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jconrel.2017.10.043","article-title":"Efficient therapy for refractory Pompe disease by mannose 6-phosphate analogue grafting on acid alpha-glucosidase","volume":"269","author":"Basile","year":"2018","journal-title":"J Control Release"},{"issue":"1","key":"10.1007\/s13311-018-0655-y_bib108","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-26913-4","article-title":"Lysosomal targeting enhancement by conjugation of glycopeptides containing mannose-6-phosphate glycans derived from glyco-engineered yeast","volume":"8","author":"Kang","year":"2018","journal-title":"Sci Rep"},{"issue":"2","key":"10.1007\/s13311-018-0655-y_bib109","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ymgme.2011.02.006","article-title":"Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle","volume":"103","author":"Koeberl","year":"2011","journal-title":"Mol Genet Metab"},{"issue":"2","key":"10.1007\/s13311-018-0655-y_bib110","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ymgme.2011.11.005","article-title":"beta2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease","volume":"105","author":"Koeberl","year":"2012","journal-title":"Mol Genet Metab"},{"issue":"5","key":"10.1007\/s13311-018-0655-y_bib111","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1096\/fj.13-241893","article-title":"Adjunctive albuterol enhances the response to enzyme replacement therapy in late-onset Pompe disease","volume":"28","author":"Koeberl","year":"2014","journal-title":"FASEB J"},{"issue":"9","key":"10.1007\/s13311-018-0655-y_bib112","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.4155\/fmc.14.40","article-title":"Pharmacological chaperone therapy for lysosomal storage diseases","volume":"6","author":"Parenti","year":"2014","journal-title":"Future Med Chem"},{"issue":"11","key":"10.1007\/s13311-018-0655-y_bib113","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1038\/mt.2014.138","article-title":"A chaperone enhances blood alpha-glucosidase activity in Pompe disease patients treated with enzyme replacement therapy","volume":"22","author":"Parenti","year":"2014","journal-title":"Mol Ther"},{"issue":"24","key":"10.1007\/s13311-018-0655-y_bib114","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1093\/hmg\/ddn290","article-title":"Modulation of glycogen synthesis by RNA interference: towards a new therapeutic approach for glycogenosis type II","volume":"17","author":"Douillard-Guilloux","year":"2008","journal-title":"Hum Mol Genet"},{"issue":"4","key":"10.1007\/s13311-018-0655-y_bib115","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/hmg\/ddp535","article-title":"Restoration of muscle functionality by genetic suppression of glycogen synthesis in a murine model of Pompe disease","volume":"19","author":"Douillard-Guilloux","year":"2010","journal-title":"Hum Mol Genet"},{"issue":"8","key":"10.1007\/s13311-018-0655-y_bib116","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.4161\/auto.6.8.13378","article-title":"Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder-murine Pompe disease","volume":"6","author":"Raben","year":"2010","journal-title":"Autophagy"},{"issue":"8","key":"10.1007\/s13311-018-0655-y_bib117","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0962-8924(00)01794-3","article-title":"Regulated secretion of conventional lysosomes","volume":"10","author":"Andrews","year":"2000","journal-title":"Trends Cell Biol"},{"key":"10.1007\/s13311-018-0655-y_bib118","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a016907","article-title":"Lysosomal adaptation: how the lysosome responds to external cues","author":"Settembre","year":"2014","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"5939","key":"10.1007\/s13311-018-0655-y_bib119","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1126\/science.1174447","article-title":"A gene network regulating lysosomal biogenesis and function","volume":"325","author":"Sardiello","year":"2009","journal-title":"Science"},{"issue":"3","key":"10.1007\/s13311-018-0655-y_bib120","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.devcel.2011.07.016","article-title":"Transcriptional activation of lysosomal exocytosis promotes cellular clearance","volume":"21","author":"Medina","year":"2011","journal-title":"Dev Cell"},{"issue":"309","key":"10.1007\/s13311-018-0655-y_bib121","doi-asserted-by":"crossref","first-page":"ra9","DOI":"10.1126\/scisignal.2004754","article-title":"the nutrient-responsive transcription factor TFE3 Promotes autophagy, lysosomal biogenesis, and clearance of cellular debris","volume":"7","author":"Martina","year":"2014","journal-title":"Sci Signal"},{"issue":"1","key":"10.1007\/s13311-018-0655-y_bib122","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-15352-2","article-title":"AAV-mediated transcription factor EB (TFEB) gene delivery ameliorates muscle pathology and function in the murine model of Pompe Disease","volume":"7","author":"Gatto","year":"2017","journal-title":"Sci Rep"},{"issue":"13","key":"10.1007\/s13311-018-0655-y_bib123","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1089\/hum.1997.8.13-1555","article-title":"Retroviral transfer of acid alpha-glucosidase cDNA to enzyme-deficient myoblasts results in phenotypic spread of the genotypic correction by both secretion and fusion","volume":"8","author":"Zaretsky","year":"1997","journal-title":"Hum Gene Ther"},{"issue":"4","key":"10.1007\/s13311-018-0655-y_bib124","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/sj.gt.3300609","article-title":"Complete correction of acid alpha-glucosidase deficiency in Pompe disease fibroblasts in vitro, and lysosomally targeted expression in neonatal rat cardiac and skeletal muscle","volume":"5","author":"Pauly","year":"1998","journal-title":"Gene Ther"},{"issue":"16","key":"10.1007\/s13311-018-0655-y_bib125","doi-asserted-by":"crossref","first-page":"8861","DOI":"10.1073\/pnas.96.16.8861","article-title":"Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase","volume":"96","author":"Amalfitano","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5 Pt 1","key":"10.1007\/s13311-018-0655-y_bib126","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1006\/mthe.2002.0580","article-title":"Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors","volume":"5","author":"Fraites","year":"2002","journal-title":"Mol Ther"},{"issue":"10","key":"10.1007\/s13311-018-0655-y_bib127","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s11626-008-9138-5","article-title":"Correction of glycogenosis type 2 by muscle-specific lentiviral vector","volume":"44","author":"Richard","year":"2008","journal-title":"In Vitro Cell Dev Biol Anim"},{"key":"10.1007\/s13311-018-0655-y_bib128","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2015.23","article-title":"Disease modeling and lentiviral gene transfer in patient-specific induced pluripotent stem cells from late-onset Pompe disease patient","volume":"2","author":"Sato","year":"2015","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"4","key":"10.1007\/s13311-018-0655-y_bib129","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/gt.2009.160","article-title":"Neonatal gene transfer using lentiviral vector for murine Pompe disease: long-term expression and glycogen reduction","volume":"17","author":"Kyosen","year":"2010","journal-title":"Gene Ther"},{"issue":"5","key":"10.1007\/s13311-018-0655-y_bib130","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.hoc.2017.06.007","article-title":"Nonintegrating gene therapy vectors","volume":"31","author":"Athanasopoulos","year":"2017","journal-title":"Hematol Oncol Clin North Am"},{"issue":"6","key":"10.1007\/s13311-018-0655-y_bib131","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.ymthe.2005.01.012","article-title":"Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter","volume":"11","author":"Sun","year":"2005","journal-title":"Mol Ther"},{"issue":"23","key":"10.1007\/s13311-018-0655-y_bib132","doi-asserted-by":"crossref","first-page":"9419","DOI":"10.1073\/pnas.0902534106","article-title":"Neural deficits contribute to respiratory insufficiency in Pompe disease","volume":"106","author":"DeRuisseau","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1007\/s13311-018-0655-y_bib133","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.resp.2013.06.007","article-title":"The respiratory neuromuscular system in Pompe disease","volume":"189","author":"Fuller","year":"2013","journal-title":"Respir Physiol Neurobiol"},{"key":"10.1007\/s13311-018-0655-y_bib134","doi-asserted-by":"crossref","DOI":"10.1002\/ana.24433","article-title":"Correcting neuromuscular deficits with gene therapy in Pompe disease","author":"Todd","year":"2015","journal-title":"Ann Neurol"},{"issue":"1","key":"10.1007\/s13311-018-0655-y_bib135","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/mt.2011.214","article-title":"Spinal delivery of AAV vector restores enzyme activity and increases ventilation in Pompe mice","volume":"20","author":"Qiu","year":"2012","journal-title":"Mol Ther"},{"issue":"1","key":"10.1007\/s13311-018-0655-y_bib136","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s40478-017-0464-2","article-title":"Long-term neurologic and cardiac correction by intrathecal gene therapy in Pompe disease","volume":"5","author":"Hordeaux","year":"2017","journal-title":"Acta Neuropathologica Communications"},{"key":"10.1007\/s13311-018-0655-y_bib137","article-title":"A neuron-specific gene therapy relieves motor deficits in pompe disease mice","author":"Lee","year":"2017","journal-title":"Mol Neurobiol"},{"key":"10.1007\/s13311-018-0655-y_bib138","first-page":"1","article-title":"B-cell depletion is protective against anti-AAV capsid immune response: a human subject case study","author":"Corti","year":"2014","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"R1","key":"10.1007\/s13311-018-0655-y_bib139","doi-asserted-by":"crossref","first-page":"R61","DOI":"10.1093\/hmg\/ddr174","article-title":"Pompe disease gene therapy","volume":"20","author":"Byrne","year":"2011","journal-title":"Hum Mol Genet"},{"key":"10.1007\/s13311-018-0655-y_bib140","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2015.53","article-title":"Targeted approaches to induce immune tolerance for Pompe disease therapy","volume":"3","author":"Doerfler","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1007\/s13311-018-0655-y_bib141","article-title":"Immunomodulatory, liver depot gene therapy for Pompe disease","author":"Bond","year":"2017","journal-title":"Cell Immunol"},{"issue":"3","key":"10.1007\/s13311-018-0655-y_bib142","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/sj.mt.6300100","article-title":"Physiological correction of Pompe disease by systemic delivery of adeno-associated virus serotype 1 vectors","volume":"15","author":"Mah","year":"2007","journal-title":"Mol Ther"},{"issue":"3","key":"10.1007\/s13311-018-0655-y_bib143","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/mt.2009.305","article-title":"Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established disease","volume":"18","author":"Mah","year":"2010","journal-title":"Mol Ther"},{"issue":"4","key":"10.1007\/s13311-018-0655-y_bib144","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/mt.2013.282","article-title":"Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in pompe mice","volume":"22","author":"Elmallah","year":"2014","journal-title":"Mol Ther"},{"issue":"6","key":"10.1007\/s13311-018-0655-y_bib145","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1089\/hum.2012.250","article-title":"Phase I\/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes","volume":"24","author":"Smith","year":"2013","journal-title":"Hum Gene Ther"},{"issue":"3","key":"10.1007\/s13311-018-0655-y_bib146","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1089\/humc.2014.2514","article-title":"Phase I\/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV-GAA) gene vector in patients with Pompe disease","volume":"25","author":"Byrne","year":"2014","journal-title":"Hum Gene Ther Clin Dev"},{"issue":"Pt 2","key":"10.1007\/s13311-018-0655-y_bib147","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.expneurol.2016.07.013","article-title":"Inspiratory muscle conditioning exercise and diaphragm gene therapy in Pompe disease: Clinical evidence of respiratory plasticity","volume":"287","author":"Smith","year":"2017","journal-title":"Exp Neurol"},{"issue":"4","key":"10.1007\/s13311-018-0655-y_bib148","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1089\/humc.2017.146","article-title":"Safety of intradiaphragmatic delivery of adeno-associated virus-mediated alpha-glucosidase (rAAV1-CMV-hGAA) gene therapy in children affected by pompe disease","volume":"28","author":"Corti","year":"2017","journal-title":"Hum Gene Ther Clin Dev"},{"issue":"9","key":"10.1007\/s13311-018-0655-y_bib149","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/mt.2013.96","article-title":"Intrapleural administration of AAV9 improves neural and cardiorespiratory function in Pompe disease","volume":"21","author":"Falk","year":"2013","journal-title":"Mol Ther"},{"key":"10.1007\/s13311-018-0655-y_bib150","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2015.7","article-title":"Comparative impact of AAV and enzyme replacement therapy on respiratory and cardiac function in adult Pompe mice","volume":"2","author":"Falk","year":"2015","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"3","key":"10.1007\/s13311-018-0655-y_bib151","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1089\/humc.2015.068","article-title":"Evaluation of readministration of a recombinant adeno-associated virus vector expressing acid alpha-glucosidase in pompe disease: preclinical to clinical planning","volume":"26","author":"Corti","year":"2015","journal-title":"Hum Gene Ther Clin Dev"},{"issue":"2","key":"10.1007\/s13311-018-0655-y_bib152","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/mt.2009.195","article-title":"Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease","volume":"18","author":"Sun","year":"2010","journal-title":"Mol Ther"},{"key":"10.1007\/s13311-018-0655-y_bib153","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.omtm.2016.12.010","article-title":"Low-dose liver-targeted gene therapy for pompe disease enhances therapeutic efficacy of ERT via immune tolerance induction","volume":"4","author":"Han","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"418","key":"10.1007\/s13311-018-0655-y_bib154","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam6375","article-title":"Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid alpha-glucosidase","volume":"9","author":"Puzzo","year":"2017","journal-title":"Sci Transl Med"},{"issue":"6","key":"10.1007\/s13311-018-0655-y_bib155","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/mt.2011.34","article-title":"Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery","volume":"19","author":"Fu","year":"2011","journal-title":"Mol Ther"},{"key":"10.1007\/s13311-018-0655-y_bib156","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1146\/annurev-biochem-060815-014607","article-title":"CRISPR\/Cas9 in Genome Editing and Beyond","volume":"85","author":"Wang","year":"2016","journal-title":"Annu Rev Biochem"},{"issue":"6271","key":"10.1007\/s13311-018-0655-y_bib157","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1126\/science.aad5725","article-title":"Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy","volume":"351","author":"Long","year":"2016","journal-title":"Science"},{"issue":"6271","key":"10.1007\/s13311-018-0655-y_bib158","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1126\/science.aad5143","article-title":"In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy","volume":"351","author":"Nelson","year":"2016","journal-title":"Science"},{"issue":"3","key":"10.1007\/s13311-018-0655-y_bib159","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/mt.2015.192","article-title":"CRISPR-mediated genome editing restores dystrophin expression and function in mdx mice","volume":"24","author":"Xu","year":"2016","journal-title":"Mol Ther"},{"key":"10.1007\/s13311-018-0655-y_bib160","article-title":"Muscle-specific CRISPR\/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy","volume":"8","author":"Bengtsson","year":"2017","journal-title":"Nat Commun"},{"issue":"8","key":"10.1007\/s13311-018-0655-y_bib161","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/nm.4367","article-title":"Correction of a splicing defect in a mouse model of congenital muscular dystrophy type 1A using a homology-directed-repair-independent mechanism","volume":"23","author":"Kemaladewi","year":"2017","journal-title":"Nat Med"},{"issue":"7631","key":"10.1007\/s13311-018-0655-y_bib162","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/nature20565","article-title":"In vivo genome editing via CRISPR\/Cas9 mediated homology-independent targeted integration","volume":"540","author":"Suzuki","year":"2016","journal-title":"Nature"},{"issue":"1","key":"10.1007\/s13311-018-0655-y_bib163","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1542\/peds.2007-2222","article-title":"Early detection of Pompe disease by newborn screening is feasible: results from the Taiwan screening program","volume":"122","author":"Chien","year":"2008","journal-title":"Pediatrics"},{"issue":"6","key":"10.1007\/s13311-018-0655-y_bib164","doi-asserted-by":"crossref","first-page":"e1116","DOI":"10.1542\/peds.2008-3667","article-title":"Pompe disease in infants: improving the prognosis by newborn screening and early treatment","volume":"124","author":"Chien","year":"2009","journal-title":"Pediatrics"},{"key":"10.1007\/s13311-018-0655-y_bib165","doi-asserted-by":"crossref","DOI":"10.1016\/j.pedneo.2013.03.009","article-title":"Pompe disease: early diagnosis and early treatment make a difference","author":"Chien","year":"2013","journal-title":"Pediatr Neonatol"},{"issue":"1","key":"10.1007\/s13311-018-0655-y_bib166","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/ajmg.a.36197","article-title":"A large-scale nationwide newborn screening program for Pompe disease in Taiwan: towards effective diagnosis and treatment","volume":"164A","author":"Yang","year":"2014","journal-title":"Am J Med Genet A"},{"issue":"1","key":"10.1007\/s13311-018-0655-y_bib167","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/(SICI)1096-8628(19980827)79:1<69::AID-AJMG16>3.0.CO;2-K","article-title":"Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease","volume":"79","author":"Martiniuk","year":"1998","journal-title":"Am J Med Genet"},{"issue":"6","key":"10.1007\/s13311-018-0655-y_bib168","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/sj.ejhg.5200367","article-title":"Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling","volume":"7","author":"Ausems","year":"1999","journal-title":"Eur J Hum Genet"},{"issue":"3","key":"10.1007\/s13311-018-0655-y_bib169","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ymgme.2011.06.010","article-title":"Rapid progressive course of later-onset Pompe disease in Chinese patients","volume":"104","author":"Yang","year":"2011","journal-title":"Mol Genet Metab"},{"issue":"6","key":"10.1007\/s13311-018-0655-y_bib170","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.jpeds.2010.11.053","article-title":"Later-onset Pompe disease: early detection and early treatment initiation enabled by newborn screening","volume":"158","author":"Chien","year":"2011","journal-title":"J Pediatr"},{"issue":"10","key":"10.1007\/s13311-018-0655-y_bib171","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1002\/ajmg.a.36110","article-title":"Timing of diagnosis of patients with Pompe disease: data from the Pompe registry","volume":"161A","author":"Kishnani","year":"2013","journal-title":"Am J Med Genet A"},{"issue":"3","key":"10.1007\/s13311-018-0655-y_bib172","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ymgme.2017.09.008","article-title":"Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G \u201clate-onset\u201d GAA variant","volume":"122","author":"Rairikar","year":"2017","journal-title":"Mol Genet Metab"},{"issue":"1\u20132","key":"10.1007\/s13311-018-0655-y_bib173","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.cccn.2004.04.009","article-title":"Glycogen storage disease type II: enzymatic screening in dried blood spots on filter paper","volume":"347","author":"Chamoles","year":"2004","journal-title":"Clin Chim Acta"},{"issue":"Suppl 1","key":"10.1007\/s13311-018-0655-y_bib174","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1542\/peds.2016-0280C","article-title":"Newborn screening for pompe disease","volume":"140","author":"Bodamer","year":"2017","journal-title":"Pediatrics"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-018-0655-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-018-0655-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792301022X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S187874792301022X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-018-0655-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T19:46:30Z","timestamp":1728675990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S187874792301022X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":174,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S187874792301022X"],"URL":"https:\/\/doi.org\/10.1007\/s13311-018-0655-y","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pompe Disease: From Basic Science to Therapy","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-018-0655-y","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}